Martin Zügel

Martin Zügel MD is an experienced executive with 30 years at executive and board level in multinational healthcare companies. Dr. Zügel is a board member at Grünenthal, an international company specializing in the neuropharmacology of pain control, where he also chairs the audit committee. In addition, he is currently chairman of the board of AMW GmbH, a pioneer of the use of AI to develop biodegradable controlled-release drug delivery systems, and MESI Ltd, an IT-based medical diagnostics company developing integrated hard- and software tools for patient medical assessment. Previously, Dr. Zügel served as chairman, director, executive or advisor with several biotech companies addressing a variety of target medical indications and has also acted as advisor to biotech/pharma investors.   Earlier in his career, Dr. Zügel was CEO of Merz Pharma GmbH. During his tenure at Merz, he was instrumental in building Memantine to a blockbuster Alzheimer Drug worldwide in close collaboration with Forest Labs, Daiichi Sankyo and Lundbeck A/S and establishing a next generation pipeline. He established, with specialty Neurology and Aesthetics, two new global franchises at Merz. He was an executive board member of B. Braun Melsungen AG in charge of their global hospital supply business and held various roles at Roche in their pharmaceuticals and diagnostics division.   Dr. Zügel holds a Doctorate in Medicine from the University of Tübingen, and a Master Degree in Molecular Biology from the University of Massachusetts at Amherst.